Jensen-Munroe relapsed in 2023 and was told unfunded, $220,000-a-year drug daratumumab was her “best option”. Unable to afford that, last year she took the second option of a stem cell transplant.
Morningstar brands and products Company Portfolio ...
EU and CN sourced daratumumab. The company is now conducting comparative efficacy studies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback